159 related articles for article (PubMed ID: 18382240)
1. Clinical endpoints for drug development in prostate cancer.
Ramiah V; George DJ; Armstrong AJ
Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240
[TBL] [Abstract][Full Text] [Related]
2. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
Armstrong AJ; Febbo PG
Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
[TBL] [Abstract][Full Text] [Related]
3. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
4. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
Collette L; Burzykowski T; Schröder FH
Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
7. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
8. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
9. New drug development in metastatic prostate cancer.
Armstrong AJ; George DJ
Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623
[TBL] [Abstract][Full Text] [Related]
10. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
12. Current controversies in the treatment of high-risk prostate cancer.
Mitchell RE; Chang SS
Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.
Colloca G
Cancer Treat Rev; 2012 Dec; 38(8):1020-6. PubMed ID: 22503300
[TBL] [Abstract][Full Text] [Related]
14. Management of high risk metastatic prostate cancer: the case for novel therapies.
Brand TC; Tolcher AW
J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
16. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced prostate cancer: docetaxel and beyond.
Dreicer R
Hematol Oncol Clin North Am; 2006 Aug; 20(4):935-46, x. PubMed ID: 16861124
[TBL] [Abstract][Full Text] [Related]
20. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
